Drugs / R-3750
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07076290 | Sep 2026 → Apr 2028 expected | chronic obstructive pulmonary disease | Rise Therapeutics LLC | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07646028 | Sep 2026 → Oct 2028 expected | acute respiratory distress syndrome | Rise Therapeutics LLC | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT05666960 | Feb 2023 → Jul 2026 overdue | ulcerative colitis | Rise Therapeutics LLC | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2023-01-31 | Rise Therapeutics LLC | Regulatory Rise Therapeutics Announces FDA Clearance of its IND Application to Initiate a Phase 1 Study of an Oral Immunotherapy for the Treatment of Ulcerative Colitis risetherapeutics.com ↗
Rise Therapeutics, a biopharmaceutical company engaged in developing novel oral synthetic biology medicines, today announced that the U.S. Food and Drug Administration (FDA) has accepted its investigational new drug (IND) application to proceed with a Phase 1 clinical trial of its lead program candidate, R-3750. |
| 2021-09-01 | Rise Therapeutics LLC | Results Rise Therapeutics Announces Publication of an Important Peer-Reviewed Journal Article Related to its R-3750 Program risetherapeutics.com ↗
These studies reveal that oral delivery of Surface Layer Protein A (SlpA)-expressing L. lactis improved colitis symptoms in animal models via a unique and important immunological mechanism that reduces inflammation, improves intestinal membrane barrier function, and establishes a more diverse gut microbiome makeup. |
All press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-04-07 | Rise Therapeutics LLC | Rise Therapeutics Reports Ulcerative Colitis Dose Escalation Clinical Results for R-3750 at the Digestive Disease Week (DDW) Conference in San Diego May 3-6 risetherapeutics.com ↗ |
| 2025-01-06 | Rise Therapeutics LLC | Dose Escalation Completed for Rise Therapeutics’ R-3750 and R-2487 Clinical Trials risetherapeutics.com ↗ |
| 2023-01-31 | Rise Therapeutics LLC | Rise Therapeutics Announces FDA Clearance of its IND Application to Initiate a Phase 1 Study of an Oral Immunotherapy for the Treatment of Ulcerative Colitis risetherapeutics.com ↗ |
| 2021-09-01 | Rise Therapeutics LLC | Rise Therapeutics Announces Publication of an Important Peer-Reviewed Journal Article Related to its R-3750 Program risetherapeutics.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | R-3750 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07646028 ↗ |
| Known as | R-3750 DP | “R-3750 DP; Lactococcus lactis expressing Surface Layer Protein A (SlpA)” NCT07076290 ↗ |
| Modality | Other / unclassified | “orally taken probiotic (R-3750)” NCT07076290 ↗ |
| Route | Oral | “orally taken probiotic (R-3750)” NCT05666960 ↗ |